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Abstract
Introduction: Transforming growth factor beta (TGFb) plays a central role in morphogenesis, growth, and cell
differentiation. This cytokine is particularly important in cartilage where it regulates cell proliferation and
extracellular matrix synthesis. While the action of TGFb on chondrocyte metabolism has been extensively
catalogued, the modulation of specific genes that function as mediators of TGFb signalling is poorly defined. In the
current study, elements of the Smad component of the TGFb intracellular signalling system and TGFb receptors
were characterised in human chondrocytes upon TGFb1 treatment.
Methods: Human articular chondrocytes were incubated with TGFb1. Then, mRNA and protein levels of TGFb
receptors and Smads were analysed by RT-PCR and western blot analysis. The role of specific protein 1 (Sp1) was
investigated by gain and loss of function (inhibitor, siRNA, expression vector).
Results: We showed that TGFb1 regulates mRNA levels of its own receptors, and of Smad3 and Smad7. It
modulates TGFb receptors post-transcriptionally by affecting their mRNA stability, but does not change the Smad-3
and Smad-7 mRNA half-life span, suggesting a potential transcriptional effect on these genes. Moreover, the
transcriptional factor Sp1, which is downregulated by TGFb1, is involved in the repression of both TGFb receptors
but not in the modulation of Smad3 and Smad7. Interestingly, Sp1 ectopic expression permitted also to maintain a
similar expression pattern to early response to TGFb at 24 hours of treatment. It restored the induction of Sox9 and
COL2A1 and blocked the late response (repression of aggrecan, induction of COL1A1 and COL10A1).
Conclusions: These data help to better understand the negative feedback loop in the TGFb signalling system, and
enlighten an interesting role of Sp1 to regulate TGFb response.
Introduction
Transforming growth factor beta (TGFb) controls a
wide range of cellular responses, including differentia-
tion, cell proliferation, migration, apoptosis, extracellular
matrix remodelling and development. In cartilage, TGFb
plays a crucial role by functioning as a potent regulator
of chondrocyte proliferation and differentiation, and of
extracellular matrix deposition [1].
Biological effects of TGFb are mediated by two differ-
ent serine/threonine kinase receptors, named type I
(TbRI) and type II (TbRII), which are both required for
inducing signal transduction. Following binding of
TGFb to TbRII, the ligand-bound type II receptor forms
an oligomeric complex with the type I receptor, result-
ing in TbRI phosphorylation. Activated TbRI (also called
ALK5) in turn transduces a number of secondary sig-
nals, most notably the activation of Smad2/3. TbRI thus
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phosphorylates the receptor-regulated Smads (R-Smads)
Smad2 and Smad3, which bind to Smad4, translocate
into the nucleus and regulate gene expression in concert
with other transcriptional factors, such as specific
protein 1 (Sp1) [2,3]. Like R-Smads, the inhibitory Smad7
interacts with the activated type I TGFb receptor. In con-
trast to Smad2/3, however, Smad7 forms a stable associa-
tion with the receptor complex and prevents receptor-
mediated phosphorylation of pathway-restricted Smads,
resulting in disruption of TGFb signalling [4].
In the cartilage context, it is thought that TGFb sig-
nalling pathway plays a critical role for maintenance of
tissue homeostasis, and modification of TGFb signalling
gene expression may be a cause for articular diseases
such as osteoarthritis (OA) [5]. TbRII and Smad3, at
least, are mediators of OA, as established using in vitro
and in vivo models. Indeed, Smad3 gene mutations in
humans or targeted disruption in mice are associated
with the pathogenesis of OA [6,7]. Similarly, mice that
express a cytoplasmically truncated type II receptor,
which acts as a dominant-negative mutant, develop a
degenerative joint disease resembling human OA [8]. In
addition, in vivo OA is associated with modifications of
TbRII and Smad7 expression [9,10].
Several studies reported that TGFb levels are
increased, at least in the first stage of the disease [1,9].
We therefore wondered whether the modifications of
expression of TGFb signalling mediators observed dur-
ing OA may be due, in part, to a feedback loop of
TGFb.
Among numerous factors involved in the OA process
and known to have the ability to regulate expression of
TGFb signalling genes, Sp1 seems to be particularly
interesting. This protein is a trans-activator of cartilage-
specific genes. The Sp1 knockdown is thus associated
with reduction of collagen expression [11]. Sp1 is also
involved in the regulation of Sox9 [12]. This transcrip-
tional factor also cooperates with Smads to regulate
expression of multiple TGFb target genes [2,3,13].
In the present report, we have investigated the effect
of TGFb1 treatment on expression of TGFb signalling
genes (receptors and Smads) and downstream genes
(Sox9, COL2A1, aggrecan, COL10A1, COL1A1) in
human articular chondrocytes. We demonstrate that
whereas TGFb treatment upregulates its receptors and
Smad3 after short exposition time of TGFb1 (< 1 hour),
it causes a dramatic decrease of both TGFb receptors,
and of Smad3 expression after longer incubation. In
marked contrast, the levels of antagonistic Smad7 were
increased in TGFb-stimulated cells in all our experimen-
tal conditions. In addition, we showed that TGFb1
induces a differential response according to the duration
of treatment, with more beneficial effect for cartilage
under short TGFb exposition. We also established a role
of Sp1 transcription factor in the downregulation
of TGFb receptors, and chondrocyte response to
TGFb. Taken together, these results provide novel
insights for the auto-modulation of TGFb signalling in
chondrocytes.
Materials and methods
Reagents
Reagents were provided by Invitrogen (Bioblock Scienti-
fic, Illkirch, France) unless otherwise noted. TGFb1
(R&D Systems, Lille, France) was resuspended in PBS-
HCl. Mithramycin and actinomycin D were obtained
from Sigma-Aldrich Co. (St Quentin Fallavier, France).
Oligonucleotides were supplied by Eurogentec (Angers,
France).
Cell culture
OA human articular chondrocytes were prepared from
femoral heads of patients who underwent hip replace-
ment (ages between 63 and 81 years, median 77 years)
as previously described [14]. All donors signed the
agreement for this study according to the local ethical
committee (Comité de protection des personnes). Cells
were seeded at 4 × 104 cells/cm2 and cultured in
DMEM supplemented with 10% heat-inactivated FCS,
100 IU/ml penicillin, 100 μg/ml streptomycin and 0.25
μg/ml fungizone, in a 5% CO2 atmosphere. Cells were
cultured for 5 to 6 days in 10% FCS-containing DMEM.
Then, at confluence, the cells were incubated in
DMEM + 2% FCS for 24 hours before adding TGFb1
(1 to 10 ng/ml) in the same medium.
RNA extraction and real-time RT-PCR
Total RNA from primary human articular chondrocyte
cultures was extracted using Trizol. Following extrac-
tion, 1 μg DNase-I treated RNA was reverse transcribed
into cDNA as previously described [14]. Amplification
of the generated cDNA was performed by real-time
PCR in Applied Biosystems SDS7000 apparatus (Applied
Biosystems Inc., Courtaboeuf, France). The relative
mRNA level was calculated with the 2-ΔΔCt method. Pri-
mer sequences are presented in Table 1.
Protein extraction and western blot analysis
Cells were rinsed, and scrapped in RIPA lysis buffer
supplemented with phosphatase and protease inhibitors.
The extracts (50 μg protein) were subjected to fractiona-
tion in 10% SDS-PAGE, transferred to polyvinylidene
fluoride membranes (Amersham Biosciences, Orsay,
France), and reacted with TbRI, TbRII, Smad2/3 or
phospho-Smad2/3 polyclonal antibodies (Tebu-bio, Le
Perray en Yvelines, France). Subsequently, membranes
were incubated with appropriate secondary peroxidase-
conjugated antibody. The signals were revealed with
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SuperSignal West Pico Chemiluminescent Substrate
(Pierce Perbio Science, Brébières, France) and exposed
to X-ray film. The membranes were also reacted with
anti b-actin to verify equal loading.
Transfection experiments
Sp1 expression vector (pEVR2-Sp1) was obtained from
Dr Suske (Institut fur Molekularbiologie and tumor-
forschung, Marburg, Germany). Chondrocytes were
transiently transfected by the nucleofection method as
previously described [14]. After overnight transfection,
cells were treated with TGFb1 (5 ng/ml) in DMEM con-
taining 2% FCS. The silencing of Sp1 was performed
using a siRNA targeting Sp1 (Tebu-Bio; Sp1 siRNA (h),
sc-29487: AAUGAGAACAGCAACAACUCC) or a con-
trol sequence (UUGUCCGAACGUGUCACGUdtdt), as
previously described [13].
Statistical analysis
All experiments were repeated with different donors at
least three times with similar results, and representa-
tive experiments are shown in the figures. Data are
presented as the mean ± standard deviation. Statistical
significance was determined by Student’s t test. Differ-
ences were considered statistically significant at
P < 0.05.
Results
TGFb1 downregulates TGFb receptors and Smad3, and
upregulates Smad7
We investigated the effect of TGFb1 on mRNA expres-
sion of TGFb signalling genes in a dose-dependent man-
ner, using real-time RT-PCR (Figure 1). A 48-hour
incubation with TGFb1 significantly reduced the expres-
sion of both TGFb receptors and Smad3, whereas the
Smad7 mRNA level was increased. These effects were
maximal at 1 ng/ml, except for TbRII for which the
maximal effect was observed only at doses above
5 ng/ml. No significant effect was observed on Smad2
and Smad4.
TGFb1 differentially regulates expression of its receptors
and Smad3 according to duration of incubation
A time-course study (Figure 2a) revealed that, at mRNA
levels, TGFb1 quickly upregulates its own receptors and
Smad3, since it increases their expression as soon as
30 minutes of treatment. For longer treatments, TGFb1
exerted the opposite effect and downregulated TGFb
receptors (after 24 hours of incubation) as well as
Smad3 (after 3 hours of incubation). On the contrary,
TGFb1 upregulated Smad7 expression whatever the
time of incubation.
Furthermore, western blot analysis (Figure 2b) showed
that TbRII is downregulated after 24 hours whereas
TbRI protein expression is decreased as soon as 1 hour
after TGFb1 treatment. In addition, as expected, TGFb1
induced Smad2/3 phosphorylation - but this effect is
transient since we were no longer able to detect phos-
phorylated Smad2/3 after 3 hours or 24 hours of treat-
ment with TGFb1.
TGFb exerts differential effects on matrix genes and Sox9
according to duration of treatment
To evaluate the importance of the regulation of TGFb
pathways in cartilage homeostasis, we analysed mRNA
expression of matrix genes (collagens type II, type I, and
type X, and aggrecan) after increased duration of treat-
ment (from 1 to 48 hours) (Figure 3). TGFb1 acted with
various kinetics according to the considered genes. It
induced COL2A1 expression in a biphasic manner (at
3 hours and after 24 hours of treatment, with no stimu-
lation for 6 hours of incubation). TGFb1 repressed
aggrecan expression after 6 hours of treatment, and
upregulated COL1A1 as soon as 1 hour of incubation.
Table 1 Primer sequences for the present study
Primer Sequence (5’ to 3’)
Sense Antisense
TbRI TTAAAAGGCGCAACCAAGAAC GTGGTGATGAGCCCTTCGAT
TbRII GACATCAATCTGAAGCATGAGAACA GGCGGTGATCAGCCAGTATT
Smad2 GCTGTTTTCCTAGCGTGGCTT TCCAGACCCACCAGCTGACT
Smad3 GCATCAGCCGCTTCTCAAGT ATCTCCCCACCATCACCTCC
Smad4 CCTTCTGGAGGAGATCGCT TCAATGGCTTCTGTCCTGTGG
Smad7 AATGTGTTTTCTAGATTCCCAACTTCTT CACTCTCGTCTTCTCCTCCCAGTA
Sp1 AGAATTGAGTCACCCAATGAGAACA GTTGTGTGGCTGTGAGGTCAAG
COL2A1 GGCAATAGCAGGTTCACGTACA CGATAACAGTCTTGCCCCACTT
COL1A1 CACCAATCACCTGCGGTACAGAA CAGATCACGTCATCGCACAAC
COL10A1 CCTGGTATGAATGGACAGAAAGG CCCTGAGGGCCTGGAAGA
Aggrecan TCGAGGACAGCGAGGCC TCGAGGGTGTAGCGTGTAGAGA
Sox9 CCC ATG TGG AAG GCA GAT G TTC TGA GAG GCA CAG GTG ACA
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Concerning hypertrophic markers of cartilage, TGFb1
induced collagen type X expression after 24 hours of
incubation. We also focused our attention on Sox9, a
major transcription factor for the chondrocyte pheno-
type, and found that TGFb1 induced its expression only
for 1 hour of incubation.
TGFb1 enhances TGFb receptor mRNA turnover, but does
not modify that of Smads
Modifications of gene expression under TGFb treatment
could be due to an increased degradation rate and/or a
reduced transcription. We therefore asked whether
TGFb1 affects mRNA decay of TbRI, TbRII, Smad3 and
Figure 1 Transforming growth factor beta 1 (TGFb1) downregulates TGFb receptors and Smad3, and upregulates Smad7. Human
articular chondrocytes (HAC) were cultured for 5 to 6 days in 10% FCS-containing DMEM. They were then incubated in DMEM + 2% FCS with
increasing doses of transforming growth factor beta 1 (TGFb1) for 48 hours. TGFb receptor type I (TbRI), TGFb receptor type II (TbRII), Smad2,
Smad3, Smad4 and Smad7 mRNA were analysed by real-time RT-PCR. The modulation of mRNA expression was expressed relative to the
controls (not treated), after normalisation to the GAPDH signal. *, P < 0.05, **, P < 0.01, ***, P < 0.001.
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Figure 2 Transforming growth factor beta 1 regulation of receptors and Smad3 expression according to incubation duration.
(a) Human articular chondrocytes (HAC) were cultured as in Figure 1 and incubated with 5 ng/ml transforming growth factor beta 1 (TGFb1) for
different times. At the end of incubations, TGFb receptor type I (TbRI), TGFb receptor type II (TbRII), Smad3 and Smad7 mRNA levels were
assayed by real-time RT-PCR. (b) In addition, TbRI, TbRII, Smad2/3 and phosphorylated Smad2/3 protein expression were analysed by western
blot analysis. *, P < 0.05, **, P < 0.01, ***, P < 0.001.
Baugé et al. Arthritis Research & Therapy 2011, 13:R23
http://arthritis-research.com/content/13/1/R23
Page 5 of 13
Smad7. Human articular chondrocytes were incubated
with actinomycin D, a transcription inhibitor, in addi-
tion to TGFb (Figure 4). The half-lives of Smad3 and
Smad7 mRNA, which were approximately 3.5 hours
and 45 minutes, respectively, were not significantly
modified by TGFb. On the contrary, inhibition of de
novo transcription clearly showed that TGFb reduced
the mRNA half-life of both TGFb receptors. Indeed,
the TbRI half-life is about 20 minutes but was reduced
to 10 minutes when chondrocytes were incubated with
TGFb, and the TbRII mRNA half-life is 45 minutes for
control cells and was reduced by almost 80% after
TGFb treatment.
Sp1 mediates TGFb-induced modulation of TGFb
receptors
As mentioned above, Sp1 is important for cartilage
metabolism. We therefore analysed the effect of TGFb1
on Sp1 expression. We showed that TGFb strongly
reduces Sp1 mRNA levels in a dose-dependent and
time-dependent manner (Figure 5).
To further investigate the putative role of Sp1, TGFb
signalling gene expression was analysed in the presence
of mithramycin, an inhibitor of DNA binding of Sp1
family members. Inhibition of Sp1 binding for 24 hours
mimics TGFb-induced repression of receptor expression,
whereas it does not affect Smad expression (Figure 6a).
Figure 3 Transforming growth factor beta differential effects on matrix genes and Sox9 according to treatment duration. Human
articular chondrocytes (HAC) were cultured and incubated as Figure 2. COL1A1, COL2A1, COL10A1, aggrecan and Sox9 mRNA levels were then
determined by RT-PCR. C, control. *, P < 0.05, **, P < 0.01, ***, P < 0.001.
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Figure 4 Transforming growth factor beta 1 (TGFb1) enhances TGFb receptors mRNA turnover. Subconfluent human articular
chondrocytes (HAC) were incubated with DMEM + 2% FCS for 24 hours. Thereafter, transforming growth factor beta 1 (TGFb1) or vehicle were
added in the presence of actinomycin D (10 μg/ml). Cells were then harvested at the indicated times for RT-PCR.
Figure 5 Transforming growth factor beta reduces specific protein 1 mRNA levels dose and time dependently. Human articular
chondrocytes (HAC) were cultured for 5 to 6 days in 10% FCS-containing DMEM. They were then incubated in DMEM + 2% FCS for 24 hours,
before addition of increased concentrations of transforming growth factor beta 1 (TGFb1) or vehicle. mRNA levels of specific protein 1 (Sp1)
were analysed by real time RT-PCR. HAC were also treated with 5 ng/ml TGFb and the Sp1 mRNA level was determined. *, P < 0.05, **, P < 0.01,
***, P < 0.001.
Baugé et al. Arthritis Research & Therapy 2011, 13:R23
http://arthritis-research.com/content/13/1/R23
Page 7 of 13
To confirm the specific role of Sp1 in these regulations,
gain and loss of function experiments were performed.
First, silencing of Sp1 by siRNA for 24 hours led to inhibi-
tion of both TGFb receptor expression but did not modify
Smad3 and Smad7 expression (Figure 6b). In contrast,
forced expression of Sp1 for 24 hours did not change TbRI
and TbRII expression but counteracted TGFb-induced
repression on these genes, whereas it did not affect Smad
expression either in the presence or in the absence of
TGFb (Figure 6c). The depletion of Sp1 by siRNA and the
overexpression of Sp1 in pEVR2-Sp1 transfected cells were
checked by western blot analysis (Figure 7) [13].
Sp1 ectopic expression permits maintaining a similar
expression pattern as early response to TGFb even after
24 hours of treatment
Since ectopic expression of Sp1 permits one to counter-
act the inhibition of TbRI and TbRII expression induced
by long treatment with TGFb, we hypothesised that it
may also affect the expression of downstream genes. We
therefore investigated the expression of matrix genes
after 24 hours of incubation with TGFb1 in cells that
had been transfected with Sp1 expression vector or con-
trol vector. Ectopic expression of Sp1 modified cell
responses to TGFb. In Sp1 transfected chondrocytes,
24-hour treatment with TGFb induced COL2A1 and
Sox9 upregulation but was not able to downregulate
aggrecan. Additionally, Sp1 ectopic expression blocked
the upregulation of COL10A1 and COL1A1. Interest-
ingly, the gene expression pattern induced by TGFb1 at
24 hours under Sp1 ectopic expression (Figure 8) is
similar to the early effect of TGFb1 at 1 hour in
untransfected cells (Figure 3).
Discussion
To our knowledge, the present study is the first systema-
tic analysis of regulation by TGFb on gene expression of
its own receptors and Smads, in human articular chon-
drocytes. Our study shows that TGFb exerts a differential
effect on the transcription of genes implicated in the
canonical Smads pathway. While TGFb upregulates its
receptors and Smad3 for short incubation (at least at
mRNA level), it downregulates them in the long term. In
addition, it upregulates Smad7 and does not significantly
alter Smad2 and Smad4 expression. This positive and
negative feedback loop of the TGFb pathway induces dif-
ferential response of chondrocytes to TGFb. The
mechanisms responsible for modulation of Smads and
for TGFb receptor expression seem to be different.
Indeed, TGFb downregulates both receptors, at least by
modifying the mRNA stability. This process appears
slowly (after 24 hours of treatment). On the contrary,
TGFb1 quickly regulates Smad3 and Smad7 mRNA levels
by a mechanism independent of mRNA stability.
Our results suggest that following TGFb1 administra-
tion a rapid activation of TGFb signalling occurs, charac-
terised by phosphorylation of Smad2/3 and upregulation
of TbRI, TbRII and Smad3 (at least at mRNA level).
Thereafter, a negative feedback loop of the TGFb1 signal-
ling pathway occurs with a decline of these receptors and
R-Smad expression and a simultaneous rise in the inhibi-
tory Smad7 level. The activation of P-Smad2/3 and upre-
gulation of Smad7 after 30 minutes of TGFb treatment
are consistent with observations from Jimenez’s group
obtained with human and bovine chondrocytes [15].
The downregulation of TGFb receptors by its own
ligand is controversial, and is dependent on cell type as
well as on duration of TGFb1 incubation. In lung fibro-
blasts, TGFb1 induced an increased type I receptor
expression by enhancing the transcription of this gene
[16], whereas its expression is not modulated or down-
regulated in osteoblasts [17,18]. Similarly, TbRII can be
downregulated or upregulated by its own ligand [18-20].
In addition, in osteoblasts TGFb1 reduces the amount
of specific TbRII at the cell surface but does not affect
the mRNA steady-state level [21].
We have established that, in human OA chondrocytes,
TGFb acts, at least in part, by strongly decreasing the
mRNA stability of its receptors. This rapid turnover
potentially allows the receptor rate to change rapidly in
response to its own ligand. We cannot, however,
exclude the possibility that TGFb downregulates its
receptors also at the transcriptional and translational
levels.
Concerning Smad effectors, our results are consistent
with data obtained in normal skin fibroblasts [22] -
which demonstrated that TGFb treatment causes an
upregulation of antagonistic Smad7, and a dramatic
decrease in Smad3 mRNA expression. Interestingly, the
mRNA level of the closely related Smad2 was not
affected by 48 hours of treatment with TGFb1. A differ-
ential regulation between R-Smads has already been
described in lung epithelial and mesangial cells [23,24]
and may lead to a variation in the cell response accord-
ing to the level of TGFb. Similar to findings obtained in
fibroblasts [22] or in mesangial cells [24], we established
that the downregulation of Smad3 mRNA expression in
TGFb-treated chondrocytes was not due to decreased
transcript stability, suggesting a transcriptional effect of
TGFb. Further experiments, such as nuclear run-on or
gene reporter assays, would be required to definitively
state this hypothesis.
In contrast to Smad3, Smad7 mRNA expression was
rapidly and markedly induced by TGFb. These findings
are agreement with reports describing Smad7 as an
immediate-early gene target of TGFb in MV1Lu cells,
HaCaT cells [4] and skin fibroblasts [22]. Increased
expression of the inhibitor Smad7 has been associated
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Figure 6 Specific protein 1 mediates transforming growth factor beta (TGFb)-induced modulation of TGFb receptors. (a) Subconfluent
cultures of chondrocytes were treated for 24 hours in the presence or absence of mithramycin (150 nM). TGFb receptor type I (TbRI), TGFb
receptor type II (TbRII), Smad3 and Smad7 expression was analysed at the mRNA level by real-time RT-PCR. (b) Human articular chondrocytes
(HAC) were also nucleofected with specific protein 1 (Sp1) siRNA oligonucleotides or control sequence. Thereafter, the medium was replaced
with DMEM + 10% FCS for 24 hours. Total RNA was then extracted and real-time RT-PCR analysis was performed. Histograms represent the
relative TbRI, TbRII, Smad3 or Smad7 mRNA levels versus GAPDH. (c) HAC were transfected overnight with pEVR2-Sp1 (or with insertless plasmid
as controls). Thereafter, media were replaced with DMEM + 2% FCS for 24 hours in the absence or the presence of transforming growth factor
beta 1 (TGFb1) (5 ng/ml). Therefore, TbRI, TbRII, Smad3 or Smad7 mRNA levels were analysed and expressed as relative expression versus
GAPDH. *, P < 0.05, **, P < 0.01, ***, P < 0.001.
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with inhibition of TGFb signalling. Smad7 could nega-
tively regulate TGFb signalling; on one hand by inhibit-
ing R-Smad activation by TbRI or by enhancing TbRI
degradation in the cytoplasm, and on the other hand by
disrupting the formation of the TGFb-induced func-
tional Smad-DNA complex in the nucleus [25].
These TGFb-induced modifications on expression of
TGF receptors and Smads may participate in the chon-
drocyte-phenotype changes observed in OA, a pathology
associated, at least in the first stage, with an increase in
the TGFb level [9]. Modifications of Smad3 expression
are associated with OA [6,7], and its expression stimu-
lates type II collagen synthesis caused by TGFb1 [26].
Moreover, activation of Smad pathways by transfection
with a dominant-negative Smad7 retroviral vector or
constitutively active TbRII abolished retinoic acid-
induced inhibition of chondrogenesis, suggesting that
TGFb receptor/Smad signalling is essential for this pro-
cess [27]. Furthermore, ectopic expression of TbRII
restores TGFb sensitivity and increases aggrecan and
col2 expression, in IL1-treated or passaged chondro-
cytes, respectively ([14] and unpublished personal data).
Our experiments indicate that TGFb1 exerts a differ-
ential effect on profiling of gene expression in chondro-
cytes according to the duration of treatment. A short
TGFb1 administration (1 hour) induces Sox9 expression,
followed, after 3 hours, by induction of collagen type II
expression. This effect was transient, but a second peak
of collagen II expression appears after 24 hours of incu-
bation of TGFb1. These data suggest that at least two
different mechanisms are responsible for cell response
to TGFb. A short TGFb administration may activate the
Smad2/3 pathway (upregulation of TbRI, TbRII and
Smad3, and phosphorylation of Smad2/3), leading to an
increase of Sox9, which, in turn, may induce collagen
type II expression. Thereafter, a negative feedback loop
occurs, characterised by a reduction of TbRI, TbRII and
Smad3 expression and simultaneous induction of the
inhibitory Smad7. This feedback leads to blockage of
Smad2/3-mediated TGFb signalling and reduction of
Sox9, and furthermore to reduced collagen type II
expression.
On the contrary, longer incubation leads an additional
response to TGFb but with a different pattern of matrix
gene expression. This late response is associated with
increased atypical collagen expression (COL1A1 and
COL10A1) and reduction of aggrecan expression. These
data suggest that a noncanonical pathway could be
involved in this late response to TGFb. Several pathways
may be implied. In particular, the reduction of TbRI
expression may change the ratio between TbRI and
ALK1, another type I TGFb receptor recently identified
in chondrocytes, favouring TGFb signalling via the
Smad1/5/8 route and, subsequently, chondrocyte term-
inal differentiation [28,29].
Finally, in the present report we show that Sp1 is
involved in the regulation of TGFb receptors and cell
response to TGFb. TGFb acts controversially on Sp1
expression. Previous data obtained in rabbit chondro-
cytes showed that TGFb decreases Sp1 expression and
binding activity [30], whereas recent studies indicate
that TGFb induces Sp1 in skin fibroblasts [31]. Our data
show that Sp1 is downregulated in human chondrocytes,
suggesting that this negative effect does not depend on
the species but is cell-type specific.
The mechanism by which TGFb regulates Sp1 expres-
sion is still unclear. In particular, the role of Smads in the
regulation of Sp1 promoter activity is not known. Analy-
sis of the Sp1 promoter (region -2,000 to +1) with
Patch_Search [32], however, shows numerous putative
binding sites for Smad3 and Smad4 in the 1,000 base pair
upstream transcription initiation site of the Sp1 gene. An
extensive study will be required to determine whether
Smads directly or indirectly regulate Sp1 expression.
Besides, a recent study shows that Smads bind in associa-
tion with Sp1 to the CC(GG)-rich TGFb1 responsive ele-
ment of the human a1 type I collagen promoter that
lacks the classical Smad recognition element, thus enhan-
cing the binding of Sp1 and in this manner activating the
collagen promoter [33]. Numerous studies indicate also
Figure 7 Depletion and overexpression of specific protein 1 by western blot analysis. Human articular chondrocytes (HAC) were treated as
in Figure 6b,c. At the end of the incubations, protein was extracted and Sp1 protein levels were determined by western blot analysis.
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Figure 8 Gene expression pattern induced by transforming growth factor beta 1 under Sp1 ectopic expression. Human articular
chondrocytes (HAC) were nucleofected with pEVR2 or pEVR2-Sp1. Thereafter, the media were replaced with DMEM + 2% FCS for 24 hours
before adding transforming growth factor beta 1 (TGFb1) (5 ng/ml) for an additional 24 hours of incubation. Total RNA was then extracted and
real-time RT-PCR analysis was performed. Histograms represent the relative COL1A1, COL2A1, COL10A1, aggrecan or Sox9 mRNA levels versus
GAPDH.
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that Sp1 cooperate with Smads to regulate the expression
of TGFb target genes [3,31,34,35].
Importantly, restoration by Sp1 of TGFb receptor
expression after inhibition by TGFb1 strongly suggests
that inhibition of Sp1 by TGFb is a potential cause of
TGFb-mediated suppression. These results were in
agreement with previous reports that demonstrate Sp1
is a transactivator of both TGFb receptors [36,37].
Moreover, a key role of Sp1 in the Smad7 induction by
TGFb was recently established in pancreatic cancer cells
[3]. In our study, however, Sp1 does not regulate Smad7
expression, suggesting that the regulatory mechanism of
Smad7 is cell specific.
Interestingly, Sp1 ectopic expression permits one to
maintain, even after 24 hours of treatment, the early cell
response to TGFb (induction of Sox9, COL2A1) and to
counteract the late response (upregulation of COL1A1,
COL10A1, repression of aggrecan). These data suggest
that targeting Sp1 expression in association to TGFb
treatment might be an innovative strategy to maintain
or induce the chondrocyte phenotype.
Conclusions
The present study enlightens a mechanism of feedback
loop controlling TGFb responses in human OA chon-
drocytes. Contrary to previous studies, which examined
one particular gene, we investigated the TGFb-induced
expression of both TGFb receptors and Smads, and the
molecular mechanism involved. We show that brief
administration of TGFb induces its signalling with upre-
gulation of TGFb receptors and Smad3, which is asso-
ciated with Sox9 and COL2A1 induction. On the
contrary, a long incubation with TGFb downregulates
its own receptors by decreasing the mRNA stability,
reduces the Smad3 expression and upregulates the inhi-
bitor Smad7. In addition, long treatments do not induce
Sox9 expression but upregulate atypical cartilage matrix
genes such as COL1A1 and COL10A1. We also provide
information about the mechanism involved in this regu-
lation. We showed the implication of the transcriptional
factor Sp1 in the repression of both TGFb receptors but
not in the modulation of Smad3 and Smad7. In addi-
tion, we demonstrated the involvement of Sp1 in both
early and late response of these cells to TGFb. Sp1 ecto-
pic expression permitted one to maintain the early
response of OA chondrocytes to TGFb at 24 hours of
treatment. Together, these data provide an overall view
of the feedback loop of the TGFb signal in human
articular chondrocytes, and highlight an interesting role
of Sp1 in regulating the TGFb response.
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